The Role of Cabozantinib as a Therapeutic Option for Hepatocellular Carcinoma: Current Landscape and Future Challenges

The systemic treatment of advanced hepatocellular carcinoma (HCC) has significantly changed over the last years, with the introduction of two new standard-of-care first-line treatments (lenvatinib and the combination of atezolizumab and bevacizumab) and the success of several new agents in second li...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Alessio, Antonio, Prete, Maria Giuseppina, Cammarota, Antonella, Personeni, Nicola, Rimassa, Lorenza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018438/
https://www.ncbi.nlm.nih.gov/pubmed/33824862
http://dx.doi.org/10.2147/JHC.S268310

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018438/
https://www.ncbi.nlm.nih.gov/pubmed/33824862
http://dx.doi.org/10.2147/JHC.S268310

Ejemplares similares